Premium
A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non‐Hodgkin's lymphoma
Author(s) -
Brereton Harmar D.,
Young Robert C.,
Longo Dan L.,
Kirkland Leland R.,
Berard Costan W.,
Jaffe Elaine S.,
Devita Vincent T.,
Johnson Ralph E.
Publication year - 1979
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197906)43:6<2227::aid-cncr2820430611>3.0.co;2-j
Subject(s) - procarbazine , medicine , vincristine , prednisone , cyclophosphamide , combination chemotherapy , chemotherapy , oncology , chop , lymphoma , gastroenterology
Thirty‐nine untreated patients with either lymphocytic or nodular mixed/nodular histiocytic non‐Hodgkin's lymphoma, stage II‐IV, were randomized to treatment with total body irradiation (TBI), 100 rads in 10 fractions over 12 days, plus combination chemotherapy with either cyclophosphamide, vincristine and prednisone (CVP) or cyclophosphamide, vincristine, procarbazine and prednisone (C‐MOPP) or to treatment with combination chemotherapy (CVP or C‐MOPP) alone. Remission rate and duration were comparable for both treatment groups; thus the use of both treatment modalities ab initio provides no therapeutic advantage.